NCT06547957

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

A First-in-Human Open-label, Phase I Dose Escalation and Expansion Cohort Study of EOS301984 as Monotherapy and in Combination With Other,Anticancer Treatments in Participants With Advanced Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: iTeos Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	EOS301984	Multiple doses of EOS301984
DRUG	Anti-PD-1 monoclonal antibody	Multiple doses of EOS301984 in combination with Anti-PD-1

Timeline

• Start date: 2023-07-07
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2024-08-09
• Last updated: 2025-08-13

Locations

6 sites across 1 country: Belgium